Sobi secures NHS reimbursement for Ravicti
Rare disease group Swedish Orphan Biovitrum (Sobi) says it has gained NHS England reimbursement for Ravicti for long-term management of urea-cycle disorders (UCDs) in adults and children.
Read More
Tag: Ravicti
Four new medicines cleared for use on NHS Scotland
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
